Oncothyreon Inc (USA) news

   Watch this stock
Showing stories 1 - 10 of about 77   

Articles published

ONTY 1.58 -0.01 (-0.63%)
price chart
Short Interest of Oncothyreon Inc (USA) Drops by 8.8%
Oncothyreon Inc (USA) (NASDAQ:ONTY) reported a drop of 8.8% or 477,810 shares in its short interest. The short figure came in at 5.9% of the total floats.
Underperforming Companies for the Week: Oncothyreon Inc (USA) , Textura Corp  Rock Hill Daily
Oncothyreon Inc (USA)(NASDAQ:ONTY) and Array Biopharma Inc (NASDAQ ...
Oncothyreon Inc (USA)(NASDAQ:ONTY), a clinical-stage biopharmaceutical company, said Friday that it has been granted an exclusive license by Array Biopharma Inc (NASDAQ:ARRY) to develop, manufacture and commercialize ONT-380 (ARRY-380), ...
Oncothyreon Announces Exclusive License Agreement With Array BioPharma ...  GlobeNewswire (press release)
Oncothyreon Pays $20M for Array BioPharma's Breast Cancer Drug  Xconomy
Related articles »  
Oncothyreon Inc (USA) Analyst Rating Update
Analysts at Zacks have given a Neutral rating on Oncothyreon Inc (USA) (NASDAQ:ONTY) with a rank of 3. The counter has received an average rating of 1.67 from 3 brokerage firms.
Update: Oncothyreon Inc (USA) Short Interest Disclosure
Oncothyreon Inc (USA) (NASDAQ:ONTY), A drop of 182,557 shares or 3.7% was seen in the short interest of Oncothyreon Inc. - Common Shares.
Pharma Stocks To Keep An Eye On: Pozen Inc. (POZN), Paratek ...
Breaking its losing streak from the past few days, the market was finally up in Wednesday's trading session, with all sectors ending in the green.
Related articles »  
Oncothyreon Inc (USA) (ONTY): Oncothyreon Offers Income To Those Accepting ...
Oncothyreon Inc. (NASDAQ:ONTY) is a biotechnology corporation that dedicates its available resources to treatments for cancer.
Related articles »  
Oncothyreaon Stock Up 18% On Cancer Drug Deal
Oncothyreon Inc (USA) (NASDAQ:ONTY) stock shot up 18% on Friday after the company announced that its breast cancer drug candidate, ONT-380, a HER2 inhibitor had demonstrated clinical activity and tolerability in previously treated patients in two Phase ...
Oncothyreon makes breast cancer drug deal with Array, stock surges Friday  Puget Sound Business Journal (Seattle) (blog)
Oncothyreon Up on Gaining License to Oncology Candidate  Zacks.com
Related articles »  
Best Biotech Stocks To Buy Now [Neuralstem, Inc., Oncothyreon Inc (USA ...
In fact, Tremblay believes that strong growth in prescription drug sales, growth in FDA drug approvals, increasing orphan drug development, and an aging U.S. population are all reasons to invest in biotech stocks now. Now, penny stock investing is ...
Oncothyreon Inc (USA) (ONTY): You Might Own Oncothyreon For All The Wrong ...
A recently announced collaboration with Array BioPharma (NASDAQ:ARRY) on a small molecule HER2 inhibitor may be the best thing to happen to Oncothyreon (NASDAQ:ONTY) since the company reincorporated in the U.S. six years ago. Oncothyreon ...
What To Do With Wet Seal Inc (WTSL), Oncothyreon Inc (USA) (ONTY) And ...
Distress in the apparel retail industry has caught up with Wet Seal Inc (NASDAQ:WTSL). The company announced that its loss in 3Q more than doubled to $36 million or $0.43 per share, The retailer also disclosed that its net sale for the quarter fell ...